| Patent application number | Description | Published |
|---|
| 20080213253 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER - Disclosed are new methods for treatment of angiogenesis-related disorders. Angiogenesis-related disorders are treated by administration of a Tie1 ectodomain-binding agent and a vascular disrupting agent. | 09-04-2008 |
| 20090186031 | COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS - Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis. | 07-23-2009 |
| 20090203060 | EVALUATING MMP EXPRESSION IN PATIENT STRATIFICATION AND OTHER THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER - Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens. | 08-13-2009 |
| 20100003195 | KDR AND VEGF/KDR BINDING PEPTIDES AND THEIR USE IN DIAGNOSIS AND THERAPY - The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K | 01-07-2010 |
| 20100196361 | Method of inhibition of vascular development using an antibody - Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to treat angiogenesis-associated disorders. | 08-05-2010 |
| 20100260672 | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (CMET) AND USES THEREOF - A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed. | 10-14-2010 |
| 20100261875 | Peptides that specifically bind HGF receptor (CMET) and uses thereof - A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed. | 10-14-2010 |
| 20100266490 | Metalloproteinase Binding Proteins - Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described. | 10-21-2010 |
| 20100291001 | METALLOPROTEINASE-BINDING PROTEINS - Disclosed are antibodies that interact with a matrix metalloproteases such as MMP-26. Exemplary antibodies inhibit MMP-26 activity. These antibodies can be used, e.g., to treat or prevent metastatic disorders, hyperproliferative disorders, disorders which are characterized by excessive extracellular matrix degradation, and inflammatory disorders. | 11-18-2010 |
| 20110059105 | TIE COMPLEX BINDING PROTEINS - Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity. | 03-10-2011 |
| 20110070165 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - The invention provides compositions and methods for therapeutic and diagnostic applications. | 03-24-2011 |
| 20110165145 | IGF-II/IGF-IIE BINDING PROTEINS - Proteins that bind to IGF-II and/or IGF-IIE and methods of using such proteins are described. Also disclosed are new methods for treatment of cancer. Cancer is treated by administration of an IGF-II/IGF-IIE binding protein and an additional therapy such as a growth hormone/growth hormone releasing hormone pathway modulator or epidermal growth factor receptor inhibitor. | 07-07-2011 |
